Iron aggravates hepatic insulin resistance in the absence of inflammation in a novel db/db mouse model with iron overload.


Journal

Molecular metabolism
ISSN: 2212-8778
Titre abrégé: Mol Metab
Pays: Germany
ID NLM: 101605730

Informations de publication

Date de publication:
09 2021
Historique:
received: 05 02 2021
revised: 31 03 2021
accepted: 09 04 2021
pubmed: 20 4 2021
medline: 8 3 2022
entrez: 19 4 2021
Statut: ppublish

Résumé

The molecular pathogenesis of late complications associated with type 2 diabetes mellitus (T2DM) is not yet fully understood. While high glucose levels indicated by increased HbA1c only poorly explain disease progression and late complications, a pro-inflammatory status, oxidative stress, and reactive metabolites generated by metabolic processes were postulated to be involved. Individuals with metabolic syndrome (MetS) frequently progress to T2DM, whereby 70% of patients with T2DM show non-alcoholic fatty liver disease (NAFLD), the hepatic manifestation of MetS, and insulin resistance (IR). Epidemiological studies have shown that T2DM and steatosis are associated with alterations in iron metabolism and hepatic iron accumulation. Excess free iron triggers oxidative stress and a switch towards a macrophage pro-inflammatory status. However, so far it remains unclear whether hepatic iron accumulation plays a causative role in the generation of IR and T2DM or whether it is merely a manifestation of altered hepatic metabolism. To address this open question, we generated and characterized a mouse model of T2DM with IR, steatosis, and iron overload. Lepr We demonstrated that features associated with T2DM in Lepr Taken together, our data show that iron causes the worsening of symptoms associated with the MetS and T2DM. These findings imply that iron depletion strategies together with anti-diabetic drugs may ameliorate IR and diabetic late complications.

Identifiants

pubmed: 33872860
pii: S2212-8778(21)00080-6
doi: 10.1016/j.molmet.2021.101235
pmc: PMC8131719
pii:
doi:

Substances chimiques

Blood Glucose 0
Receptors, Leptin 0
leptin receptor, mouse 0
Iron E1UOL152H7

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

101235

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier GmbH.. All rights reserved.

Auteurs

Sandro Altamura (S)

Department of Pediatric Hematology, Oncology and Immunology - University of Heidelberg, Heidelberg, Germany; Molecular Medicine Partnership Unit, Heidelberg, Germany.

Katja Müdder (K)

Department of Pediatric Hematology, Oncology and Immunology - University of Heidelberg, Heidelberg, Germany.

Andrea Schlotterer (A)

Fifth Medical Department - Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany; European Center of Angioscience (ECAS) - Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany.

Thomas Fleming (T)

Department of Internal Medicine I and Clinical Chemistry, University of Heidelberg, Heidelberg, Germany; German Center for Diabetes Research (DZD), Neuherberg, Germany.

Elena Heidenreich (E)

Centre for Organismal Studies (COS), University of Heidelberg, Heidelberg, Germany.

Ruiyue Qiu (R)

Department of Pediatric Hematology, Oncology and Immunology - University of Heidelberg, Heidelberg, Germany.

Hans-Peter Hammes (HP)

Fifth Medical Department - Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany; European Center of Angioscience (ECAS) - Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany.

Peter Nawroth (P)

Department of Internal Medicine I and Clinical Chemistry, University of Heidelberg, Heidelberg, Germany; German Center for Diabetes Research (DZD), Neuherberg, Germany; Institute for Diabetes and Cancer at Helmholtz Zentrum Munich, Neuherberg, Germany.

Martina U Muckenthaler (MU)

Department of Pediatric Hematology, Oncology and Immunology - University of Heidelberg, Heidelberg, Germany; Molecular Medicine Partnership Unit, Heidelberg, Germany. Electronic address: martina.muckenthaler@med.uni-heidelberg.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH